Fast Assessment of Solutions, Therapeutics, Pharmaceuticals, and SupplieS (FASTPASS) Innovative Solutions Opening
Responses closed . Full description on SAM.gov.
Overview
- Response deadline
- 4:00 PM EST
- Posted
- October 21, 2026
- Notice type
- Solicitation
- NAICS
- 541715: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Agency
- Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH
Notice details
- Office
- ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (ARPA-H)
- Place of performance
- District of Columbia, 20005
- Last updated
- Oct 28, 2026
- First published
- Last updated on SAM.gov
Identifiers
- Solicitation number
- ARPA-H-SOL-26-160
- Notice ID
- 1479442e64d740b59cc92c717bd329bc
Description
October 21, 2026
FASTPASS ISO, ARPA-H-SOL-26-160, Amendment 01
The purpose of Amendment 01 is to:
(1) Revise Section 1.2 of the Appendix C.3: Cost Proposal Narrative Model;
(2) Rename Attachment D: Cost Proposal Workbook to Appendix D: Cost Proposal Workbook; and
(3) Revise item 4 under the General tab of Appendix D: Cost Proposal Workbook to correct a typographical error.
No other changes were made to the body of the ISO or appendices.
See attached FASTPASS ISO, ARPA-H-SOL-26-160, Amendment 01.
_________________________
August 20, 2026
The Advanced Research Projects Agency for Health (ARPA-H) Fast Assessment of Solutions, Therapeutics, Pharmaceuticals, and SupplieS (FASTPASS) program aims to develop a near real-time, non-destructive, AI-enabled system for screening pharmaceutical products and inputs through their packaging at ports of entry and other supply-chain nodes.
Interested parties are invited to review the attached FASTPASS Innovative Solutions Opening, ARPA-H-SOL-26-160.
Award Overview
No prior contract identified
No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.
Contacts
Contracting Officer
Primary Contact
Documents
Files (11)
- Download
FASTPASS ISO ARPA-H-SOL-26-160 Amendment 01.pdf
187 KBAdded in Solicitation version 2Posted - Download
Appendix A_Program and Technical Description.pdf
142 KBAdded in Solicitation version 1Posted - Download
APPENDIX-C3-Cost-Proposal-Model Amendment 01.docx
51 KBAdded in Solicitation version 2Posted - Download
Appendix B_FASTPASS_Pre-Proposal Discussion Template and Instructions.pptx
13 MBAdded in Solicitation version 1Posted - Download
APPENDIX-C.0-Proposal Format and Instructions.docx
66 KBAdded in Solicitation version 1Posted - Download
APPENDIX-C.1-Technical and Management Proposal Model.docx
46 KBAdded in Solicitation version 1Posted - Download
APPENDIX-C.2-Task Description Document Model.docx
37 KBAdded in Solicitation version 1Posted - Download
APPENDIX-D-Cost-Proposal-Workbook Amendment 01.xlsx
98 KBAdded in Solicitation version 2Posted - Download
APPENDIX C.4_Milestone Payment Schedule Model.xlsx
20 KBAdded in Solicitation version 1Posted - Download
APPENDIX E-Draft OT Agreement.docx
114 KBAdded in Solicitation version 1Posted - Download
APPENDIX F_Administrative National Policy Document.docx
94 KBAdded in Solicitation version 1Posted
Lifecycle
- 1Version 1Solicitation
Fast Assessment of Solutions, Therapeutics, Pharmaceuticals, and SupplieS (FASTPASS) Innovative Solutions Opening
- 2Version 2SolicitationCurrent
Fast Assessment of Solutions, Therapeutics, Pharmaceuticals, and SupplieS (FASTPASS) Innovative Solutions Opening
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
Amendment 3 (11/09/2026): ISO updates to Part II - Technical Areas & Requirements: TA1: Edits to the "Target" language for the Retrospective Data Access metric. Amendment 2 (10/29/2026): Numerous changes including, but not limited to,: ISO updates in Parts I, II, III and VI; TA1 clarifications; TA2 updates; TA4 updates; Q&A link added Provides Attachment B1 for TA4 Proposal Requirements and Proposal Volume Templates. Provides Attachment A2 for TA1 Solution Summary Requirements and Attachment A3 for TA2 Solution Summary Requirements. Amendment 1 (10/14/2026): Update due dates and/or times of all TAs SPECTRA will identify and act on autism trajectories, the evolving developmental paths individuals follow across the lifespan from the prenatal period through aging, spanning autism characteristics, co-occurring conditions, and functional outcomes together with the genetic, biological, behavioral, iatrogenic (medical influences), environmental factors and their nonlinear interactions. Rather than examining these factors in isolation, SPECTRA will examine how they combine and interact, including their nonlinear interactions, to produce autism and its co-occurring conditions over time. SPECTRA will also develop technologies that serve two purposes at once: extending reliable assessment beyond the clinic while improving everyday communication, function, and quality of life. The same tools people use to live more fully will also generate the data that drive measurement and personalized care. | - | Solicitation | 12/02/2026 |
The Advanced Research Projects Agency for Health (ARPA-H) is soliciting proposals from small business concerns (SBCs) that possess the research and development (R&D) expertise to conduct innovative research that will contribute toward ARPA-H mission needs, Small Business Innovation Research (SBIR), and Small Business Technology Transfer (STTR) program objectives. Please see the cover page of the attachment "SBIR_STTR_BAA_FY26" for applicable Stage 1 and Stage 2 deadlines for each open topic. Please see the Attachment H "ARPA-H_SBP_Government_Answered_Questions" for responses to the Q&A period. The purposes of the SBIR and STTR programs are to: (a) stimulate technological innovation; (b) strengthen the role of small business in meeting Federal research/research & development (R/R&D) needs; (c) foster and encourage participation by socially and economically disadvantaged small business concerns and women-owned business concerns; and (d) increase private sector commercialization of innovations derived from Federal R/R&D, thereby increasing competition, productivity and economic growth. For purposes of the SBIR and STTR programs, a small business concern is any business concern that, on the date of award, (1) is organized for profit, with a place of business located in the United States, which operates primarily within the United States or which makes a significant contribution to the United States economy through payment of taxes or use of American products, materials or labor; (2) is in the legal form of an individual proprietorship, partnership, limited liability company, corporation, joint venture, association, trust or cooperative, except that where the form is a joint venture, there must be less than 50 percent participation by foreign business entities in the joint venture; (3) more than 50% directly owned and controlled by one or more individuals (who are citizens or permanent resident aliens of the United States), other business concerns (each of which is more than 50% directly owned and controlled by individuals who are citizens or permanent resident aliens of the United States), or any combination of these; OR more than 50% owned by multiple venture capital operating companies, hedge funds, private equity firms, or any combination of these. No single venture capital operating company, hedge fund, or private equity firm may own more than 50% of the concern; AND, (4) has, including its affiliates, no more than 500 employees. Note: This size standard is established by law for the SBIR program, regardless of the NAICS Code assigned. See 13 C.F.R. § 121.702. AMENDMENT 01 - July 8, 2026: Amendment 01 of this solicitation extends the deadline for Stage 1 Solution Summaries from July 10, 2026 to July 17, 2026. This amendment answers conforming questions that were submitted prior to the Q&A deadline via Attachment H. This amendment adds/revises the following soliciation sections: Add change log, revise sections 2.3, 3.1, 3.2, 4.2, 4.3, 4.4, 5.0, 5.4, add section 5.5, revise section 8, topic 6, and topic 7. AMENDMENT 02 - August 17, 2026: Amendment 02 of this solicitation publishes the Stage 2 submission deadline for Topics 01, 02, 03, 04, 06, and 07. This amendment revises language in the following sections: cover page, 2.2, 2.3, 2.4, 2.6, 2.8, and 8. Amendment 02 corresponds with Stage 1 encourage/discourage letter distribution for topics 01, 02, 03, 04, 06, and 07. Please check your email inbox for your Stage 1 encourage/discourage letters on or around August 17, 2026. Topic 05 Stage 1 letters and Stage 2 submission deadline will be distributed at a later date. AMENDMENT 03 - September 1, 2026: Amendment 03 of this solicitation publishes the Stage 2 submission deadline for Topic 05. This amendment revises language in the following sections: cover page and 8. Amendment 03 corresponds with Stage 1 encourage/discourage letter distribution for topic 05. Please check your email inbox for your Stage 1 encourage/discourage letters on or around September 1, 2026. Amendment 03 updates Attachment B Cost Proposal Spreadsheet Template. AMENDMENT 04 - September 10 2026: Amendment 04 of this solicitation revises the Stage 2 submission deadline for Topics 01, 02, 03, 04, 06, and 07. This amendment revises language in the following section: cover page and 8. This amendment updates Attachment B Cost Proposal Spreadsheet Template. AMENDMENT 05 - September 11 2026: Amendment 05 of this solicitation revises the Stage 2 submission deadline for Topics 01, 02, 03, 04, 06, and 07. This amendment revises language in the following section: cover page and 8. This amendment updates Attachment B Cost Proposal Spreadsheet Template. This amendment also unprotects Attachment B Cost Proposal Spreadsheet and updates the instructions sheet. THE FOLLOWING ARE THE CURRENTLY OPEN RESEARCH TOPICS. PLEASE SEE SECTION 8 OF THE BAA FOR FURTHER INFORMATION ARPA-H 01 - Development of an annual test to inform women about their future fertility - The purpose of this topic is to discover new biomarkers that provide women with actionable data for fertility planning. Results from this work will help inform the program manager regarding the feasibility of future programs focused on enhancing natural fertility before the need of IVF and guiding the development of women’s health monitoring and improvement tools. This work will develop a diagnostic test that can assess fertility status and generate an estimated timeline for the onset of infertility. This topic seeks to develop a test that is affordable, suitable for at least annual use, and provides user-friendly results for patients and care teams to support childbearing decisions. ARPA-H 02 - Versatile Bioadhesives - The purpose of this topic is to develop next-generation bioadhesive platforms that can safely and reliably seal, bond, and repair a wide range of tissues in challenging clinical conditions, including wet, bloody, and mechanically dynamic environments. These platforms may also be designed to deliver biologics or small molecules as part of treatment. The goal is to create bioadhesives with key performance attributes such as strong tissue adhesion, controlled degradation, reversibility, biocompatibility, and broad compatibility across multiple tissues and organs. If successful, this topic could enable widely deployable solutions for hemostasis, leak prevention, tissue repair, and device fixation, ultimately helping reduce complications and improve patient outcomes across many care settings ARPA-H 03 - Universal Platform for Living Adaptive Toxin-removal (UNI-PLAT) - The purpose of this topic area is to catalyze the development of a universal, “plug-and-play” synthetic biology platform that enables next-generation microbial chassis capable of performing a broad array of programmable functions. While this solicitation primarily uses toxin removal as a proof-of-concept in relation to chronic disease management, the platform is intended to be adaptable to a range of challenges across industries such as environmental remediation, biomanufacturing, agriculture, holistic medicine, and therapeutic discovery. The broader goal is to create a stable, reliable, and easily reprogrammable microbial platform that demonstrates potential for cross-sector impact beyond the initial use case. ARPA-H 04 - Breaking Ground: The First Curative, Durable, Non-Surgical Therapy for Endometriosis – The purpose of this topic aims to develop treatments for endometriosis that are non-surgical. Proposers are expected to develop novel, non-surgical therapies to decrease the size or deactivate endometrial implants, to decrease inflammation cause by implants, and / or prevent growth or regrowth of the lesions. Broadly, this should be a novel, non-surgical, curative treatment for endometriosis. ARPA-H 05 - ARPA-H Lineage Topic - The purpose of this topic supports the advancement, commercialization, and translation of technologies that originated from ARPA-H funded efforts. It is intended to help small businesses and startups develop viable products based on these technologies. ARPA-H’s goal is to give small businesses an off-ramp to finish developing their technology/product, explore secondary or interim applications of the technology, and time to achieve self-sufficiency. ARPA-H 06 - Rapid Comprehensive Diagnostic Test for Multi-System Autoimmune Disease -The purpose of this topic is to spur the development of novel, rapid diagnostic assays for multi-system autoimmune disease, which represents an unmet healthcare need. Moreover, in its ideal embodiment this diagnostic test might allow typical primary care physicians to diagnose and predict tissue-specific autoimmune disease manifestations, thereby streamlining referral of the patient to a specialist. This goal is made more feasible by recent technological developments including the ability to detect tissue-specific signatures of immune-mediated stress by assessing circulating cells and/or tissue-specific molecular products. ARPA-H 07 - Virtual Human Brain for the Development of Neurosurgical Robotics - The purpose of this topic aims to take a first step toward AI-assisted intracranial microsurgery by creating a high-resolution, physically and anatomically accurate virtual human brain. | - | Pre-Solicitation | 10/01/2026 |
Amendment 4 The ISO was updated to extend the Solution Video submission deadline to August 12, 2026 and the Full Proposal submission deadline to September 17, 2026 for intake Group 1. See page 3 of the full text ISO for more information. Amendment 3 (1) Appendix B was updated to remove track changes (2) Appendix C4 was updated to remove an erroneous comment. Amendment 2 (1) Instructions on how to submit a Solution Video were added to the ISO (see pages 7-8). (2) Information related to the Video Captions file was added to Appendix B.0 (Solution Video Format and Instructions). (3) The instructions in Appendix B.1 (Template for Supplemental Slides) were simplified, and a Cost Summary slide was added (see Slide 7). (4) Appendix C.3 was updated to reference "Phase" rather than "Year" for clarity. (5) The Administation and National Policy document in Appendix C.4 was replaced with an updated document. Amendment 1 The ISO was updated with the new webinar and webinar registration dates. Effort Description: TIGAR Exploratory Topic will forge entirely new paths to stabilizing regenerative tissues and organs by seeding the development of enabling technologies that can unlock temperature-flexible storage in increasingly larger and more complex biological systems. Solutions may involve any combination of new materials, artificial intelligence/machine learning, high-throughput screening methods, biological interventions, devices, processing methods, analytical technology, and packaging approaches that can overcome current roadblocks and yield a leap in the ability to store and distribute complex biologics, without introducing high cost or complexity. Strategies that reduce reliance on strictly controlled temperature zones and can ensure safe storage in a range of environmental conditions are preferred. While long-term temperature-flexible storage is ideal, any advance that removes logistical hurdles or establishes shelf-life stability at easy to maintain temperatures (preferably non-cryogenic) will be considered. Innovations at the cellular level without a strategy for deployment in thick tissues will not be considered. Please ensure to follow this opportunity for any updates. For more information on the TIGAR Exploratory Topic visit: https://arpa-h.gov/explore-funding/initiatives-and-sprints/tigar For information on Proposer's Day details and registration information, please see Special Notice ARPA-H-SN-26-142 | - | Solicitation | 12/08/2026 |
June 23, 2026: The purpose of Amendment #1 is to update ISO Section 5.4.4 CRITERIA 4: ASSESSMENT OF PROPOSED COST/PRICE. All other terms and conditions remain unchanged. The Advanced Research Projects Agency for Health (ARPA-H) posts this funding opportunity in support of the Brain Repair of Any Injured Neural Structure (BRAINS) Exploratory Topic program. ARPA-H anticipates multiple awards with Other Transaction award types resulting from this announcement. Interested parties are invited to review the Innovative Solutions Opening (ISO) ARPA-H-SOL-26-148. Parties interested in submitting a proposal in response to the ARPA-H BRAINS ISO are required (mandatory) to submit a solution summary. No awards will be made, or funding provided as a result of a solution summary submission. Intake Group 1: Solution Summaries Due: July 9th, 2026, 5:00 PM Full Proposals Due: August 6th, 2026, 5:00PM Intake Group 2: Solution Summaries Due: January 7th, 2027, 5:00 PM Full Proposals Due: February 6th, 2027, 5:00PM | - | Solicitation | 02/26/2027 |
The Proactive Health Office (PHO) at ARPA-H is seeking solutions to improve the healthspan and health outcomes of Americans prior to the onset of disease and/or the development of diminished quality of life from illness. Specifically, PHO hypothesizes that 1) population-level improvements in access to and uptake of disease prevention and wellness-promoting behaviors and 2) development of novel early-detection methods and prophylactic interventions could drastically improve the health of American throughout their lives, and 3) that system level innovations are required for delivery of proactive health effectively. Solution summary submissions must be submitted to: https://solutions.arpa-h.gov Questions must be submitted to: https://solutions.arpa-h.gov/Ask-A-Question/ Proposal submission should be submitted to: https://solutions.arpa-h.gov/Submit-Proposal/ Amendment 4 is effective immediately; however, if an entity has previously submitted a Solution Summary and a proposal, no action is required related to changes described in the amendment. If only a Solution Summary has been submitted; any future proposal must comply with this amendment. Amendment 04 includes the following changes: Updated Administrative and National Policy Requirements document (Note other Bundle of Attachment documents are unchanged) Minor changes throughout the ISO, including, but not limited to: Updating the name from ARPA-H Solution Submission Portal to ARPA-H Solutions Site, notation in paragraph 2.3, and revised language in Section 6.1 Research Security Disclosures to align with the updated Bundle of Attachments document. | - | Solicitation | 03/06/2029 |
Additional Details
Solicitation Number
ARPA-H-SOL-26-160
Archive Date
Nov 25, 2026
Office Address
Washington, DC, 20005